Hepatitis C in Renal Transplant Recipients

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prof. Dr. Alice Schmidt
• Treatments: Cyclosporine; Cyclosporins; Tacrolimus

Criteria

Inclusion Criteria:

• written informed consent

• prior renal transplantation

• current tacrolimus-based immunosuppressive regimen

• hepatitis C-infection

• age 18-70 years

Exclusion Criteria:

• current hemodialysis or peritoneal dialysis

• pregnancy or breastfeeding

• known contraindication for cyclosporine A-treatment